thalidomide and Cancer of Lung studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research Excerpts

Excerpt	Relevance	Reference
"In this open-label, multicentre, randomised phase 3 study, eligible patients had proven malignant pleural or peritoneal mesothelioma and had received a minimum of four cycles of first-line treatment containing at least pemetrexed, with or without cisplatin or carboplatin, and had not progressed on this treatment."	9.17	Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. ( Baas, P; Buikhuisen, WA; Burgers, JA; Custers, FL; Gans, SJ; Groen, HJ; Korse, CM; Nowak, AK; Pavlakis, N; Schouwink, JH; Schramel, FM; Strankinga, WF; van Klaveren, RJ; Vincent, AD, 2013)
"Our results demonstrate that thalidomide is highly effective in controlling delayed nausea and vomiting episodes in patients induced by moderately emetogenic chemotherapy."	9.14	[The effect of thalidomide in preventing delayed nausea and vomiting induced by GP regimen of chemotherapy for non-small cell lung cancer]. ( Ha, MW; Li, JP; Liu, XM; Wu, Q; Xing, YD; Yu, YL; Zhu, ZT, 2009)
"The aim of this study was to determine the antitumour activity and toxicity of thalidomide in patients with metastatic melanoma."	9.11	Phase II study of thalidomide in patients with metastatic melanoma. ( Legha, SS; Pawlak, WZ, 2004)
" We reported an advanced lung adenocarcinoma female patient, who developed a Grade 3 HFS after a third-line treatment with apatinib of 250 mg for 10 days, the patient developed intolerable pain with pruritus."	7.96	Apatinib-induced Grade 3 hand-foot syndrome in advanced lung adenocarcinoma successful treated with thalidomide: A case report. ( Du, LY; Jia, YM; Lei, KJ; Li, T; Qiu, Y; Ren, Y; Wang, SB, 2020)
"To discuss and assess the clinical value of treating lung cancer cachexia with thalidomide combined with cinobufagin."	7.88	Clinical study on thalidomide combined with cinobufagin to treat lung cancer cachexia. ( Bao, Y; Bu, K; Chen, X; Lu, Y; Qin, S; Xie, M, 2018)
"We reported two cases of hepatocellular carcinoma (HCC) with lung metastases who were treated with a combination of thalidomide and cyproheptadine."	7.78	Unexpected remission of hepatocellular carcinoma (HCC) with lung metastasis to the combination therapy of thalidomide and cyproheptadine: report of two cases and a preliminary HCC cell line study. ( Chen, SC; Feng, CW; Feng, YM; Hsu, CD, 2012)
"Thalidomide has been reported to have antitumor activity for treating metastatic hepatocellular carcinoma (HCC)."	7.73	Thalidomide for treating metastatic hepatocellular carcinoma: a pilot study. ( Bang, SM; Cho, EK; Han, SH; Kim, JH; Kim, KK; Kim, SS; Kwon, OS; Kwon, SY; Lee, JH; Lee, JJ; Lee, JN; Nam, E; Park, SH; Park, YH; Shin, DB, 2006)
" Although thalidomide did not affect growth of primary tumors in mice after xenotransplantation of canine osteosarcoma cells, our findings indicate that thalidomide may interfere with the ability of embolic tumor cells to complete the metastatic process within the lungs."	7.72	Effect of thalidomide on growth and metastasis of canine osteosarcoma cells after xenotransplantation in athymic mice. ( Baldwin, JM; Detrisac, CJ; Farese, JP; Fox, LE; Roberts, SL; Van Gilder, JM, 2004)
"Simultaneous multiple myeloma (MM) and pulmonary adenocarcinoma is a rare occurrence, and thus, treatment is a challenge."	5.46	Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma: A case report. ( Deng, M; Lin, Q; Mei, Z; Song, Y; Yang, J; Yin, Q; Zhu, X; Zuo, W, 2017)
"The addition of thalidomide to pyrotinib is expected to increase the clinical benefit in advanced NSCLC patients with HER2 exon 20 insertions, and reduce the incidence of pyrotinib-related diarrhea."	5.41	Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial. ( Ai, X; Chen, Z; Jian, H; Li, Z; Lu, S; Song, Z; Yu, Y; Zhou, Z, 2021)
"Curative treatment of aggressive Kaposi sarcoma (KS) with conventional chemotherapy in human immunodeficiency virus (HIV)-infected patients remains difficult."	5.39	Clinical activity of lenalidomide in visceral human immunodeficiency virus-related Kaposi sarcoma. ( Burg, S; Crickx, B; Di Lucca, J; Feldman, J; Joly, V; Lariven, S; Marinho, E; Maubec, E; Peytavin, G; Raymond, E; Sarda-Mantel, L; Steff, M, 2013)
"Thalidomide has proven to exert anti-inflammatory, anti-proliferative and anti-angiogenic activities in both neoplastic and non-neoplastic conditions."	5.38	Thalidomide attenuates mammary cancer associated-inflammation, angiogenesis and tumor growth in mice. ( Alves Neves Diniz Ferreira, M; Cândida Araújo E Silva, A; da Silva Vieira, T; Dantas Cassali, G; Fonseca de Carvalho, L; Maria de Souza, C; Passos Andrade, S; Teresa Paz Lopes, M, 2012)
"Thalidomide is reported to be an anti-angiogenic agent, which is currently in phase II clinical trials for the treatment of advanced malignancies."	5.32	Effects of thalidomide on the expression of angiogenesis growth factors in human A549 lung adenocarcinoma cells. ( Jiang, W; Li, QQ; Li, X; Liu, X; Liu, Y; Reed, E; Wang, J; Wang, Z; Zhang, Y, 2003)
"In this open-label, multicentre, randomised phase 3 study, eligible patients had proven malignant pleural or peritoneal mesothelioma and had received a minimum of four cycles of first-line treatment containing at least pemetrexed, with or without cisplatin or carboplatin, and had not progressed on this treatment."	5.17	Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. ( Baas, P; Buikhuisen, WA; Burgers, JA; Custers, FL; Gans, SJ; Groen, HJ; Korse, CM; Nowak, AK; Pavlakis, N; Schouwink, JH; Schramel, FM; Strankinga, WF; van Klaveren, RJ; Vincent, AD, 2013)
"Our results demonstrate that thalidomide is highly effective in controlling delayed nausea and vomiting episodes in patients induced by moderately emetogenic chemotherapy."	5.14	[The effect of thalidomide in preventing delayed nausea and vomiting induced by GP regimen of chemotherapy for non-small cell lung cancer]. ( Ha, MW; Li, JP; Liu, XM; Wu, Q; Xing, YD; Yu, YL; Zhu, ZT, 2009)
"The aim of this study was to determine the antitumour activity and toxicity of thalidomide in patients with metastatic melanoma."	5.11	Phase II study of thalidomide in patients with metastatic melanoma. ( Legha, SS; Pawlak, WZ, 2004)
" We reported an advanced lung adenocarcinoma female patient, who developed a Grade 3 HFS after a third-line treatment with apatinib of 250 mg for 10 days, the patient developed intolerable pain with pruritus."	3.96	Apatinib-induced Grade 3 hand-foot syndrome in advanced lung adenocarcinoma successful treated with thalidomide: A case report. ( Du, LY; Jia, YM; Lei, KJ; Li, T; Qiu, Y; Ren, Y; Wang, SB, 2020)
"To discuss and assess the clinical value of treating lung cancer cachexia with thalidomide combined with cinobufagin."	3.88	Clinical study on thalidomide combined with cinobufagin to treat lung cancer cachexia. ( Bao, Y; Bu, K; Chen, X; Lu, Y; Qin, S; Xie, M, 2018)
" In a heavily pretreated patient with advanced colorectal cancer carrying mutations in APC and KRAS genes, we show an early metabolic response and enhanced NK cell activity to monotherapy with lenalidomide."	3.80	Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy. ( Amann, A; Auer, T; Gamerith, G; Hilbe, W; Kircher, B; Loeffler-Ragg, J; Putzer, D; Schenk, B; Zwierzina, H, 2014)
"We reported two cases of hepatocellular carcinoma (HCC) with lung metastases who were treated with a combination of thalidomide and cyproheptadine."	3.78	Unexpected remission of hepatocellular carcinoma (HCC) with lung metastasis to the combination therapy of thalidomide and cyproheptadine: report of two cases and a preliminary HCC cell line study. ( Chen, SC; Feng, CW; Feng, YM; Hsu, CD, 2012)
"Thalidomide has been reported to have antitumor activity for treating metastatic hepatocellular carcinoma (HCC)."	3.73	Thalidomide for treating metastatic hepatocellular carcinoma: a pilot study. ( Bang, SM; Cho, EK; Han, SH; Kim, JH; Kim, KK; Kim, SS; Kwon, OS; Kwon, SY; Lee, JH; Lee, JJ; Lee, JN; Nam, E; Park, SH; Park, YH; Shin, DB, 2006)
" Although thalidomide did not affect growth of primary tumors in mice after xenotransplantation of canine osteosarcoma cells, our findings indicate that thalidomide may interfere with the ability of embolic tumor cells to complete the metastatic process within the lungs."	3.72	Effect of thalidomide on growth and metastasis of canine osteosarcoma cells after xenotransplantation in athymic mice. ( Baldwin, JM; Detrisac, CJ; Farese, JP; Fox, LE; Roberts, SL; Van Gilder, JM, 2004)
"This phase I/IIA study evaluated the maximum-tolerated dose (MTD), safety, and clinical benefit of pomalidomide, an immunomodulatory drug (IMiD), combined with cisplatin+etoposide chemotherapy, in treatment-naive patients with extensive-stage (ES) small-cell lung cancer (SCLC)."	2.78	A phase I study of pomalidomide (CC-4047) in combination with cisplatin and etoposide in patients with extensive-stage small-cell lung cancer. ( Beck, R; Ellis, PM; Fandi, A; Jungnelius, U; Shepherd, FA; Zhang, J, 2013)
"Patients were randomly assigned to the control arm (PC) involving two cycles of induction paclitaxel 225 mg/m(2) and carboplatin area under the curve (AUC) 6 followed by 60 Gy thoracic radiation administered concurrently with weekly paclitaxel 45 mg/m(2) and carboplatin AUC 2, or to the experimental arm (TPC), receiving the same treatment in combination with thalidomide at a starting dose of 200 mg daily."	2.77	Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. ( Belinsky, SA; Dahlberg, SE; Fitzgerald, TJ; Hoang, T; Johnson, DH; Mehta, MP; Schiller, JH, 2012)
"Thalidomide was associated with an increased risk of having a thrombotic event, mainly pulmonary embolus and deep vein thrombosis (19% thalidomide vs 10% placebo; HR = 2."	2.74	Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. ( Ali, K; Ferry, D; Hackshaw, A; James, L; Jitlal, M; Lee, SM; Middleton, G; O'Brien, M; Rudd, R; Spiro, S; Woll, PJ, 2009)
"NP regimen combined with thalidomide can significantly prolong the median time to tumor progression in patients with advanced NSCLC."	2.74	[Randomized study of thalidomide combined with vinorelbine and cisplatin chemotherapy for the treatment of advanced non-small cell lung cancer]. ( Gu, AQ; Han, BH; Qi, DJ; Shen, J; Song, YY; Xin, Y; Xiong, LW; Zhang, XY, 2009)
"In this large trial of patients with NSCLC, thalidomide in combination with chemotherapy did not improve survival overall, but increased the risk of thrombotic events."	2.74	Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer. ( Gilligan, D; Gower, N; Hackshaw, A; Jitlal, M; Lee, SM; Ottensmeier, C; Price, A; Rudd, R; Spiro, S; Woll, PJ, 2009)
"Treatment with thalidomide was not associated with a significant improvement in survival of SCLC patients."	2.73	Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. ( Breton, JL; David, P; Gameroff, S; Genève, J; Gervais, R; Janicot, H; Maraninchi, D; Pujol, JL; Quoix, E; Tanguy, ML; Westeel, V, 2007)
"Thalidomide was well-tolerated and median time on thalidomide treatment was 7."	2.73	Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer. ( Buchler, T; Ellis, P; Hackshaw, A; James, L; Lee, SM; Snee, M, 2008)
"Thalidomide was given orally every evening starting on day 1 until progressive disease; the starting dose was 200 mg per day, which was escalated by 100 mg per week if tolerated (maximum 1000 mg per day)."	2.72	Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer. ( Atkins, JN; Bearden, JD; Case, D; Giguere, JK; Miller, AA, 2006)
"Lung cancer is the leading cause of cancer-related mortality in the United States."	2.45	Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer. ( Horn, L; Sandler, AB, 2009)
"It is now well established that cancer growth is increased by angiogenic factors and that inhibition of angiogenesis decreases growth and metastatic potential."	2.42	[Anti angiogenesis]. ( Akaza, H; Blackledge, G; Carmichael, J; Isonishi, S; Kakeji, Y; Kurebayashi, J; Nakagawa, M; Nakamura, S; Ohashi, Y; Saijo, N; Sone, S; Tsuruo, T; Yamamoto, N, 2004)
"Lung cancer is a major public health problem and the leading cause of cancer-related death worldwide."	2.41	Angiogenesis inhibitors in lung cancer. ( Herbst, RS; Kim, ES, 2002)
"Small cell lung cancer is a tumor that has a very poor prognosis without treatment."	2.41	Management of small cell lung cancer. ( Karapetis, C; Steer, C; Yip, D, 2001)
"Thalidomide is a widely used anti-angiogenic and immunomodulatory drug with anticancer effects."	1.51	Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC. ( Guo, Z; Huang, C; Huang, H; Jiang, L; Liao, Y; Liu, J; Liu, Y; Wang, X; Xia, X; Zhang, F, 2019)
"Simultaneous multiple myeloma (MM) and pulmonary adenocarcinoma is a rare occurrence, and thus, treatment is a challenge."	1.46	Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma: A case report. ( Deng, M; Lin, Q; Mei, Z; Song, Y; Yang, J; Yin, Q; Zhu, X; Zuo, W, 2017)
"Lung cancer is one of the major causes of cancer-related mortality worldwide, and non-small-cell lung cancer is the most common form of lung cancer."	1.46	Anticancer effects of novel thalidomide analogs in A549 cells through inhibition of vascular endothelial growth factor and matrix metalloproteinase-2. ( Agwa, H; El-Aarag, B; Kasai, T; Masuda, J; Seno, M; Zahran, M, 2017)
"Multiple myeloma is a clonal B-cell malignancy, characterised by proliferation of plasma cells and secretion of paraproteins."	1.43	Pleural effusion as a manifestation of multiple myeloma. ( Iqbal, N; Majid, H; Shaikh, MU; Tariq, MU, 2016)
"Fourteen patients with advanced lung cancer were scheduled to receive chemotherapy combined with thalidomide."	1.43	Thalidomide Combined with Chemotherapy in Treating Patients with Advanced lung Cancer. ( Huang, XE; Li, L, 2016)
"Curative treatment of aggressive Kaposi sarcoma (KS) with conventional chemotherapy in human immunodeficiency virus (HIV)-infected patients remains difficult."	1.39	Clinical activity of lenalidomide in visceral human immunodeficiency virus-related Kaposi sarcoma. ( Burg, S; Crickx, B; Di Lucca, J; Feldman, J; Joly, V; Lariven, S; Marinho, E; Maubec, E; Peytavin, G; Raymond, E; Sarda-Mantel, L; Steff, M, 2013)
"Thalidomide has proven to exert anti-inflammatory, anti-proliferative and anti-angiogenic activities in both neoplastic and non-neoplastic conditions."	1.38	Thalidomide attenuates mammary cancer associated-inflammation, angiogenesis and tumor growth in mice. ( Alves Neves Diniz Ferreira, M; Cândida Araújo E Silva, A; da Silva Vieira, T; Dantas Cassali, G; Fonseca de Carvalho, L; Maria de Souza, C; Passos Andrade, S; Teresa Paz Lopes, M, 2012)
"Thalidomide has potent anti-inflammatory and anti-angiogenic properties."	1.38	Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide. ( Brown, NJ; Jitlal, M; Lee, SM; Tin, AW; Woll, PJ; Young, RJ, 2012)
"Pulmonary MALT lymphoma is a rare disease entity and generally follows an indolent clinical course."	1.33	Very good partial response in a patient with MALT-lymphoma of the lung after treatment with low-dose thalidomide. ( Chott, A; Gisslinger, H; Kees, M; Metz-Schimmerl, S; Raderer, M, 2005)
"Chemotherapy for the treatment of brain metastases arising from non-small cell lung cancer (NSCLC) has been limited by poor efficacy and high toxicity."	1.33	[A case report of chemotherapy with thalidomide, celecoxib and gemcitabine in the treatment of patients with brain metastases from lung cancer]. ( Hada, M; Horiuchi, T, 2005)
"Thalidomide was begun at 50 mg, p."	1.33	Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury. ( Anscher, MS; Clough, R; Crawford, J; Dewhirst, MW; Dunphy, F; Garst, J; Herndon, JE; Larrier, N; Marino, C; Marks, LB; Shafman, TD; Vujaskovic, Z; Zhou, S, 2006)
"Thalidomide has been reported to have antiangiogenic and antimetastatic effects."	1.33	A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB. ( Chen, CC; Lin, YC; Shun, CT; Wu, MS, 2006)
"Lung cancer is the leading cause of cancer-related death in developed countries."	1.32	The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines: possible involvement in the PPARgamma pathway. ( Andreola, F; De Luca, LM; DeCicco, KL; Tanaka, T, 2004)
"Thalidomide is reported to be an anti-angiogenic agent, which is currently in phase II clinical trials for the treatment of advanced malignancies."	1.32	Effects of thalidomide on the expression of angiogenesis growth factors in human A549 lung adenocarcinoma cells. ( Jiang, W; Li, QQ; Li, X; Liu, X; Liu, Y; Reed, E; Wang, J; Wang, Z; Zhang, Y, 2003)

Research

Studies (89)

Authors

Clinical Trials (7)

Trial Overview

Trial Outcomes

Duration of Response

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (2.25)	18.7374
1990's	4 (4.49)	18.2507
2000's	46 (51.69)	29.6817
2010's	29 (32.58)	24.3611
2020's	8 (8.99)	2.80

Authors	Studies
Shah, JH	1
Swartz, GM	1
Papathanassiu, AE	1
Treston, AM	1
Fogler, WE	1
Madsen, JW	1
Green, SJ	1
Xia, Y	1
Wang, WC	1
Shen, WH	1
Xu, K	1
Hu, YY	1
Han, GH	1
Liu, YB	1
Ai, X	1
Song, Z	1
Jian, H	1
Zhou, Z	1
Chen, Z	1
Yu, Y	2
Li, Z	1
Lu, S	1
Gong, K	1
Guo, G	1
Beckley, NA	1
Yang, X	1
Zhang, Y	3
Gerber, DE	1
Minna, JD	1
Burma, S	1
Zhao, D	1
Akbay, EA	1
Habib, AA	1
O Aboelez, M	1
Belal, A	1
Xiang, G	1
Ma, X	1
Donarska, B	1
Sławińska-Brych, A	1
Mizerska-Kowalska, M	1
Zdzisińska, B	1
Płaziński, W	1
Łączkowski, KZ	1
Ren, Y	1
Li, T	1
Du, LY	1
Qiu, Y	1
Wang, SB	1
Lei, KJ	1
Jia, YM	1
Zong, D	1
Gu, J	1
Cavalcante, GC	1
Yao, W	1
Zhang, G	1
Wang, S	1
Owonikoko, TK	1
He, X	1
Sun, SY	1
Miyazato, K	1
Tahara, H	1
Hayakawa, Y	1
Wang, GH	1
Wu, PF	1
Zhang, LH	2
Fang, P	1
Chen, Y	1
Zuo, G	1
Wu, YQ	1
Wang, SH	1
Sun, GP	1
Li, Q	1
Liu, Y	3
Polton, G	1
Finotello, R	1
Sabattini, S	1
Rossi, F	1
Laganga, P	1
Vasconi, ME	1
Barbanera, A	1
Stiborova, K	1
Rohrer Bley, C	1
Marconato, L	1
Xie, M	1
Chen, X	1
Qin, S	1
Bao, Y	2
Bu, K	1
Lu, Y	1
Sun, X	1
Xu, Y	1
Wang, Y	1
Chen, Q	1
Liu, L	1
Fattore, D	1
Annunziata, MC	1
Panariello, L	1
Marasca, C	1
Fabbrocini, G	1
Xia, X	1
Liao, Y	1
Guo, Z	1
Huang, C	1
Zhang, F	1
Jiang, L	1
Wang, X	1
Liu, J	1
Huang, H	1
Buikhuisen, WA	1
Burgers, JA	1
Vincent, AD	1
Korse, CM	1
van Klaveren, RJ	1
Schramel, FM	1
Pavlakis, N	1
Nowak, AK	1
Custers, FL	1
Schouwink, JH	1
Gans, SJ	1
Groen, HJ	1
Strankinga, WF	1
Baas, P	1
Pass, HI	1
Lee, SM	6
Hackshaw, A	5
de Souza, CM	1
Araújo e Silva, AC	1
de Jesus Ferraciolli, C	1
Moreira, GV	1
Campos, LC	1
dos Reis, DC	1
Lopes, MT	1
Ferreira, MA	1
Andrade, SP	1
Cassali, GD	1
Steff, M	1
Joly, V	1
Di Lucca, J	1
Feldman, J	1
Burg, S	1
Sarda-Mantel, L	1
Peytavin, G	1
Marinho, E	1
Crickx, B	1
Raymond, E	1
Lariven, S	1
Maubec, E	1
Gamerith, G	1
Auer, T	1
Amann, A	1
Putzer, D	1
Schenk, B	1
Kircher, B	1
Hilbe, W	1
Zwierzina, H	1
Loeffler-Ragg, J	1
Lowney, AC	1
McAleer, MA	1
Kelly, S	1
McQuillan, RJ	1
Togni, A	1
Rütten, M	1
Bley, CR	1
Hurter, K	1
Li, L	1
Huang, XE	1
Iqbal, N	1
Tariq, MU	1
Shaikh, MU	1
Majid, H	1
El-Aarag, B	1
Kasai, T	1
Masuda, J	1
Agwa, H	1
Zahran, M	1
Seno, M	1
Zuo, W	1
Zhu, X	1
Yang, J	1
Mei, Z	1
Deng, M	1
Lin, Q	1
Song, Y	1
Yin, Q	1
Kassam, A	1
Mandel, K	1
Lu, L	1
Payvandi, F	1
Wu, L	1
Hariri, RJ	1
Man, HW	1
Chen, RS	1
Muller, GW	1
Hughes, CC	1
Stirling, DI	1
Schafer, PH	1
Bartlett, JB	1
Harshman, LC	1
Li, M	1
Srinivas, S	2
Israyelyan, A	1
Shannon, EJ	1
Baghian, A	1
Kearney, MT	1
Kousoulas, KG	1
Chen, JR	1
Tzen, CY	1
Yang, YC	1
Horn, L	1
Sandler, AB	1
Grushka, JR	1
Ryckman, J	1
Mueller, C	1
Roessingh, Ade B	1
Walton, JM	1
St Vil, D	1
Laberge, JM	1
Bernard, C	1
Nguyen, VH	1
Puligandla, PS	1
Woll, PJ	3
Rudd, R	2
Ferry, D	1
O'Brien, M	1
Middleton, G	1
Spiro, S	2
James, L	2
Ali, K	1
Jitlal, M	3
Rüegg, C	1
Peters, S	1
Gu, AQ	1
Han, BH	1
Zhang, XY	1
Shen, J	1
Qi, DJ	1
Xiong, LW	1
Xin, Y	1
Song, YY	1
Dudek, AZ	1
Lesniewski-Kmak, K	1
Larson, T	1
Dragnev, K	1
Isaksson, R	1
Gupta, V	1
Maddaus, MA	1
Kratzke, RA	1
Ottensmeier, C	1
Gilligan, D	1
Price, A	1
Gower, N	1
Jazieh, AR	1
Komrokji, R	1
Gupta, A	1
Patil, S	1
Flora, D	1
Knapp, M	1
Issa, M	1
Abdel Karim, N	1
Musallam, KM	1
Taher, AT	1
Reck, M	1
Gatzemeier, U	1
Yu, YL	1
Zhu, ZT	1
Li, JP	1
Ha, MW	1
Liu, XM	1
Wu, Q	1
Xing, YD	1
Zhang, H	2
Chen, J	1
Zhao, H	1
Zeng, X	1
Qing, C	1
Liu, WM	1
Gravett, AM	1
Dalgleish, AG	1
Pregun, I	1
Bodoky, G	1
Rácz, K	1
Tulassay, Z	1
Hoang, T	1
Dahlberg, SE	1
Schiller, JH	1
Mehta, MP	1
Fitzgerald, TJ	1
Belinsky, SA	1
Johnson, DH	1
Decker, RH	1
Lynch, TJ	1
Young, RJ	1
Tin, AW	1
Brown, NJ	1
Maria de Souza, C	1
Fonseca de Carvalho, L	1
da Silva Vieira, T	1
Cândida Araújo E Silva, A	1
Teresa Paz Lopes, M	1
Alves Neves Diniz Ferreira, M	1
Passos Andrade, S	1
Dantas Cassali, G	1
Feng, YM	1
Feng, CW	1
Chen, SC	1
Hsu, CD	1
Ellis, PM	1
Jungnelius, U	1
Zhang, J	1
Fandi, A	1
Beck, R	1
Shepherd, FA	1
Yip, D	2
Karapetis, C	1
Steer, C	2
Raje, N	1
Anderson, KC	1
Chaudhry, V	1
Chaudhry, M	1
Crawford, TO	1
Simmons-O'Brien, E	1
Griffin, JW	1
Li, X	1
Liu, X	1
Wang, J	1
Wang, Z	1
Jiang, W	1
Reed, E	1
Li, QQ	1
Goldman, B	1
Pawlak, WZ	1
Legha, SS	1
Hada, M	2
Akaza, H	1
Nakagawa, M	1
Tsuruo, T	1
Saijo, N	1
Sone, S	1
Yamamoto, N	1
Kakeji, Y	1
Nakamura, S	1
Kurebayashi, J	1
Isonishi, S	1
Ohashi, Y	1
Blackledge, G	1
Carmichael, J	1
Farese, JP	1
Fox, LE	1
Detrisac, CJ	1
Van Gilder, JM	1
Roberts, SL	1
Baldwin, JM	1
DeCicco, KL	1
Tanaka, T	1
Andreola, F	1
De Luca, LM	1
Chua, YJ	1
Guardino, AE	1
Kees, M	1
Raderer, M	1
Metz-Schimmerl, S	1
Chott, A	1
Gisslinger, H	1
Horiuchi, T	1
Zhang, ZL	1
Liu, ZS	1
Sun, Q	1
Segers, J	1
Di Fazio, V	1
Ansiaux, R	1
Martinive, P	1
Feron, O	1
Wallemacq, P	1
Gallez, B	1
Pujol, JL	2
Anscher, MS	1
Garst, J	2
Marks, LB	1
Larrier, N	1
Dunphy, F	2
Herndon, JE	2
Clough, R	1
Marino, C	1
Vujaskovic, Z	1
Zhou, S	1
Dewhirst, MW	1
Shafman, TD	1
Crawford, J	2
Riedel, RF	1
Kelley, MJ	1
Lin, YC	1
Shun, CT	1
Wu, MS	1
Chen, CC	1
Han, SH	1
Park, SH	1
Kim, JH	2
Lee, JJ	1
Kwon, SY	1
Kwon, OS	1
Kim, SS	1
Kim, KK	1
Park, YH	1
Lee, JN	1
Nam, E	1
Bang, SM	1
Cho, EK	1
Shin, DB	1
Lee, JH	1
Dowlati, A	1
Subbiah, S	1
Cooney, M	1
Rutherford, K	1
Mekhail, T	1
Fu, P	1
Chapman, R	1
Ness, A	1
Cortas, T	1
Saltzman, J	1
Levitan, N	1
Warren, G	1
Miller, AA	1
Case, D	1
Atkins, JN	1
Giguere, JK	1
Bearden, JD	1
Breton, JL	1
Gervais, R	1
Tanguy, ML	1
Quoix, E	1
David, P	1
Janicot, H	1
Westeel, V	1
Gameroff, S	1
Genève, J	1
Maraninchi, D	1
Pérol, M	1
Arpin, D	1
Buchler, T	1
Snee, M	1
Ellis, P	1
Rossi, A	1
Gridelli, C	1
Bria, E	1
Pollard, M	1
Deaner, P	1
Stolt, CM	1
Brock, CS	1
Tchekmedyian, NS	1
Kim, ES	1
Herbst, RS	1
Roe, FJ	2
Walters, MA	2
Mitchley, BC	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Safety and Efficacy of Pyrotinib Combined With Thalidomide in Advanced Non-Small-Cell Lung Cancer With HER2 Exon 20 Insertions: A Prospective, Single-arm, Open-label Phase II Study[NCT04382300]	Phase 2	39 participants (Anticipated)	Interventional	2020-06-30	Recruiting
Phase 1/2 Study of Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors[NCT01166035]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2010-03-31	Recruiting
A Pilot Study of Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer After First-line Chemotherapy[NCT02018523]	Phase 1	7 participants (Actual)	Interventional	2014-06-30	Terminated (stopped due to Study did not enroll enough subjects to make a statistically sound conclusion.)
A Phase III Randomized, Double Blind, Placebo Controlled Trial Of Carboplatin/Etoposide With Or Without Thalidomide In Small Cell Lung Cancer (Study 12)[NCT00061919]	Phase 3	724 participants (Actual)	Interventional	2003-04-30	Completed
A Multicenter, Phase I/IIA, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose and To Evaluate the Safety Profile of CC-4047 Administered in Combination With Cisplatin and Etoposide in Patients With Extensive Disease Small Cell Lung[NCT00537511]	Phase 1/Phase 2	22 participants (Actual)	Interventional	2008-02-01	Terminated (stopped due to This study was terminated for administrative reasons.)
Randomized Phase II-III Study of Bevacizumab 7,5 mg/kg in Combination With Chemotherapy Versus Chemotherapy in Extensive-Disease Small-Cell Lung Cancer After Response to Chemotherapy : PCDE (cisPlatin - Cyclophosphamide - epiDoxorubicin - Etoposide) or PE[NCT00930891]	Phase 2/Phase 3	143 participants (Actual)	Interventional	2009-09-30	Completed
Study of Thalidomide With First-line Chemotherapy and as Maintenance Treatment of Advanced Nonsquamous NSCLC With Epidermal Growth Factor Receptor Wild-Type or Unknown Mutation Status: A Multicenter, Randomized, Prospective Clinical Trial[NCT03062800]	Phase 2	232 participants (Anticipated)	Interventional	2016-12-31	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Duration of Response was calculated from first Partial Response (PR) or Complete Response (CR) to disease progression. Duration of response was censored at the last date that the participant was known to be progression-free for: 1) participants who had not progressed at the time of analysis; 2) participants who had been removed from the treatment phase prior to documentation of progression. (NCT00537511)
Timeframe: From first Partial Response (PR) or Complete Response (CR) to disease progression (maximum of 19.4 weeks)

Maximum Tolerated Dose (MTD)

Intervention	weeks (Mean)
Pomalidomide (Overall)	13.2

The MTD was defined as the highest dose level at which no more than 1 in 6 participants experienced a dose-limiting toxicity (DLT) during the first 21-day cycle of treatment. The MTD Phase included the Treatment period (Cycle 1: Identification of the MTD) and the Extension period (Cycles 2 to 6: Confirmation of Safety of the MTD). (See Secondary Outcome Measure 2 for data on DLTs.) (NCT00537511)
Timeframe: Cycle 1 (21 days)

Number of Participants With Dose Limiting Toxicities (DLTs) During the MTD Phase

Intervention	mg (Number)
Pomalidomide (Overall)	4

For the purposes of determining the MTD (see Primary Outcome Measure), a DLT was defined as any 1 or more of the following: inability to deliver all 3 doses of cisplatin and etoposide due to toxicity; inability to deliver 14 consecutive days of daily pomalidomide dosing because the participant did not tolerate the medication due to any of the following: ≥ grade 3 non-hematological toxicity (excluding alopecia) occurring before Day 14 of pomalidomide dosing; febrile neutropenia (absolute neutrophil count [ANC] <1,000/µL and fever >101ºF, core temperature); grade 4 neutropenia of ≥7 days duration with onset on or before Day 14 of pomalidomide dosing; platelet count <25,000/µL occurring before Day 14 of pomalidomide dosing. National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE), Version 4.0, grades: 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death. (NCT00537511)
Timeframe: Cycles 1 - 6 (21-day cycles)

Overall Survival

Intervention	participants (Number)
Pomalidomide 1 mg	1
Pomalidomide 3 mg	0
Pomalidomide 4 mg	0
Pomalidomide 5 mg	2

Overall Survival was defined as time (in weeks) from enrollment to death. The median is based on Kaplan-Meier estimate, with 95% confidence intervals about the median overall survival. Overall survival was censored at the last time participant was known to be alive for those who were alive at time of analysis. (NCT00537511)
Timeframe: From enrollment through study termination (approximately 35 months)

Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the MTD (Combination Treatment) Phase

Intervention	weeks (Median)
Pomalidomide (Overall)	49.6

Adverse event (AE) = any noxious, unintended, or untoward medical occurrence occurring at any dose that may appear or worsen in a participant during the course of a study, including new intercurrent illness, worsening concomitant illness, injury, or any concomitant impairment of participant's health, including laboratory test values, regardless of etiology. Serious adverse event (SAE) = any AE which: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. TEAE = any AE occurring or worsening on or after the first treatment with any study drug. Related = suspected by investigator to be related to study treatment. National Cancer Institute [NCI] Common Toxicity Criteria for Adverse Events [CTCAE], Version 4.0, grades: 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, 5 = death. (NCT00537511)
Timeframe: Cycles 1-6 (21-day cycles). Median (full range) duration of exposure (in weeks) to pomalidomide (MTD Phase): 1 mg, 17.9 (1.0, 20.3); 3 mg, 17.0 (16.9, 22.0); 4 mg, 14.0 (0.7, 22.0); 5 mg, 13.0 (2.0, 22.1). Cisplatin and etoposide: 15.3 (0.4, 20.6).

Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Recovery Period or Maintenance (Monotherapy) Phase

Intervention	participants (Number)
	≥1 TEAE	≥1 TEAE related to pomalidomide (POM)	≥1 TEAE related to cisplatin and/or etoposide(C/E)	≥1 Grade 3 or higher (GR3+) TEAE	≥1 GR 3+ TEAE related to POM	≥1 GR 3+ TEAE related to C/E	≥1 Serious TEAE	≥1 Serious TEAE related to POM	≥1 Serious TEAE related to C/E	≥1 TEAE leading to (→) withdrawal of POM	≥1 TEAE → withdrawal of C/E	≥1 TEAE → dose reduction/interruption of POM	≥1 TEAE → dose reduction/interruption of C/E
Pomalidomide (Overall, MTD Phase)	22	22	22	22	14	20	10	7	9	6	6	15	13
Pomalidomide 1 mg	6	6	6	6	3	6	3	2	2	2	2	5	3
Pomalidomide 3 mg	4	4	4	4	2	3	1	1	1	0	1	2	3
Pomalidomide 4 mg	6	6	6	6	4	6	3	1	3	2	1	4	3
Pomalidomide 5 mg	6	6	6	6	5	5	3	3	3	2	2	4	4

Tumor Response Rate According to Response Evaluation Criteria in Solid Tumors (RECIST)

Intervention	participants (Number)
	≥1 TEAE	≥1 TEAE related to pomalidomide (POM)	≥1 TEAE related to cisplatin and/or etoposide (C/E	≥1 Grade 3 or higher (GR3+) TEAE	≥1 GR 3+ TEAE related to POM	≥1 GR 3+ TEAE related to C/E	≥1 TEAE → dose reduction/interruption of POM
Pomalidomide (Overall)	9	8	7	6	2	2	2

Investigator's best assessment of response based on RECIST criteria during the MTD phase. For target lesions: Complete Response (CR)=Disappearance of all target lesions; Partial Response (PR)=≥30% decrease in sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD; Progressed Disease (PD)=≥20% increase in sum of LD of target lesions taking as reference the smallest sum LD recorded since treatment started or the appearance of ≥1 new lesions; Stable Disease (SD)=Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum LD since treatment started. For non-target lesions: CR= Disappearance of all non-target lesions and normalization of tumor marker level; Incomplete Response/SD=Persistence of ≥1 non-target lesions and/or maintenance of tumor marker level above normal limits; PD=Appearance of ≥1 new lesions; unequivocal progression of existing non-target lesions. (NCT00537511)
Timeframe: Cycles 1 -6 (21-day cycles)

Article	Year
Antiangiogenic therapy for primitive neuroectodermal tumor with thalidomide: A case report and review of literature. Medicine, 2017, Volume: 96, Issue:51 Topics: Adolescent; Angiogenesis Inhibitors; Biopsy, Needle; Bronchoscopy; Follow-Up Studies; Humans; Immuno	2017
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer. Clinical lung cancer, 2009, Volume: 10 Suppl 1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonate	2009
Spindle epithelial tumor with thymus-like elements of the thyroid: a multi-institutional case series and review of the literature. Journal of pediatric surgery, 2009, Volume: 44, Issue:5 Topics: Abscess; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Celecoxib; Ch	2009
[Carcinoid tumors]. Orvosi hetilap, 2010, Nov-14, Volume: 151, Issue:46 Topics: 3-Iodobenzylguanidine; Antineoplastic Agents; Biomarkers, Tumor; Bronchial Neoplasms; Carcinoid Tumo	2010
Management of small cell lung cancer. Expert review of anticancer therapy, 2001, Volume: 1, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma, S	2001
Thalidomide and immunomodulatory drugs as cancer therapy. Current opinion in oncology, 2002, Volume: 14, Issue:6 Topics: Adjuvants, Immunologic; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Humans; Immun	2002
[Anti angiogenesis]. Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:4 Topics: Angiogenesis Inhibitors; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Cyclooxyg	2004
Recent advances in management of small-cell lung cancer. Cancer treatment reviews, 2004, Volume: 30, Issue:6 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benz	2004
[Angiogenesis and lung cancer]. Bulletin du cancer, 2007, Volume: 94 Spec No Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bio	2007
Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer. The European respiratory journal, 2002, Volume: 19, Issue:3 Topics: Angiogenesis Inducing Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Smal	2002
Angiogenesis inhibitors in lung cancer. Current oncology reports, 2002, Volume: 4, Issue:4 Topics: Angiogenesis Inhibitors; Angiostatins; Carcinoma, Non-Small-Cell Lung; Collagen; Cyclohexanes; Endos	2002

Article	Year
Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial. BMC cancer, 2021, Sep-16, Volume: 21, Issue:1 Topics: Acrylamides; Aminoquinolines; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocol	2021
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. The Lancet. Oncology, 2013, Volume: 14, Issue:6 Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Ca	2013
A potential new enriching trial design for selecting non-small-cell lung cancer patients with no predictive biomarker for trials based on both histology and early tumor response: further analysis of a thalidomide trial. Cancer medicine, 2013, Volume: 2, Issue:3 Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Fre	2013
The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer. American journal of clinical oncology, 2008, Volume: 31, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Carcinoma, Renal	2008
Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. Journal of the National Cancer Institute, 2009, Aug-05, Volume: 101, Issue:15 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc	2009
[Randomized study of thalidomide combined with vinorelbine and cisplatin chemotherapy for the treatment of advanced non-small cell lung cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat	2009
Phase II trial of neoadjuvant therapy with carboplatin, gemcitabine plus thalidomide for stages IIB and III non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2009, Volume: 4, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcino	2009
Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-01, Volume: 27, Issue:31 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino	2009
Phase II trial of thalidomide, irinotecan and gemcitabine in chemonaive patients with advanced non-small cell lung cancer. Cancer investigation, 2009, Volume: 27, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell	2009
[The effect of thalidomide in preventing delayed nausea and vomiting induced by GP regimen of chemotherapy for non-small cell lung cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:12 Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat	2009
Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Feb-20, Volume: 30, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Ca	2012
A phase I study of pomalidomide (CC-4047) in combination with cisplatin and etoposide in patients with extensive-stage small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013, Volume: 8, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; Lung Neo	2013
Phase II study of thalidomide in patients with metastatic melanoma. Melanoma research, 2004, Volume: 14, Issue:1 Topics: Adult; Aged; Angiogenesis Inhibitors; Disease Progression; Female; Humans; Lung Neoplasms; Male; Max	2004
A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma. BJU international, 2005, Volume: 96, Issue:4 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bone Neoplasms; Carcinoma, Renal Cell; Double-Blin	2005
Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2006, Volume: 54, Issue:3 Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols	2006
Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy. Lung cancer (Amsterdam, Netherlands), 2007, Volume: 56, Issue:3 Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Non-Small-Cell Lung; Disease Progression; Dose-Response Re	2007
Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2006, Volume: 1, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Smal	2006
Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Sep-01, Volume: 25, Issue:25 Topics: Carcinoma, Small Cell; Disease-Free Survival; Double-Blind Method; Female; Humans; Lung Neoplasms; M	2007
Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2008, Volume: 59, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Disease Progress	2008

Article	Year
Synthesis and enantiomeric separation of 2-phthalimidino-glutaric acid analogues: potent inhibitors of tumor metastasis. Journal of medicinal chemistry, 1999, Aug-12, Volume: 42, Issue:16 Topics: Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Glutarates; Indoles; Lung Neoplasm	1999
Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454-3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC. Chemico-biological interactions, 2021, Nov-01, Volume: 349 Topics: Angiogenesis Inhibitors; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Guanine Nucleotide Exchange	2021
Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids. Nature communications, 2021, 12-01, Volume: 12, Issue:1 Topics: A549 Cells; Animals; Carcinoma, Non-Small-Cell Lung; Cytokines; Disease Models, Animal; Drug Resista	2021
Design, synthesis, and molecular docking studies of novel pomalidomide-based PROTACs as potential anti-cancer agents targeting EGFR Journal of enzyme inhibition and medicinal chemistry, 2022, Volume: 37, Issue:1 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Ant	2022
Thalidomide derivatives as nanomolar human neutrophil elastase inhibitors: Rational design, synthesis, antiproliferative activity and mechanism of action. Bioorganic chemistry, 2023, Volume: 138 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Sc	2023
Apatinib-induced Grade 3 hand-foot syndrome in advanced lung adenocarcinoma successful treated with thalidomide: A case report. Dermatologic therapy, 2020, Volume: 33, Issue:2 Topics: Adenocarcinoma of Lung; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Lung Neoplasms; Pyridines;	2020
BRD4 Levels Determine the Response of Human Lung Cancer Cells to BET Degraders That Potently Induce Apoptosis through Suppression of Mcl-1. Cancer research, 2020, 06-01, Volume: 80, Issue:11 Topics: Animals; Apoptosis; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Humans; Lung Neoplasms; Mice; M	2020
Antimetastatic effects of thalidomide by inducing the functional maturation of peripheral natural killer cells. Cancer science, 2020, Volume: 111, Issue:8 Topics: Animals; Cell Differentiation; Cell Line, Tumor; Cytotoxicity, Immunologic; Disease Models, Animal;	2020
Use of erlotinib and thalidomide in advanced NSCLC patients with acquired resistance to erlotinib: A pilot study. Pathology, research and practice, 2018, Volume: 214, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small	2018
Survival analysis of dogs with advanced primary lung carcinoma treated by metronomic cyclophosphamide, piroxicam and thalidomide. Veterinary and comparative oncology, 2018, Volume: 16, Issue:3 Topics: Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Comb	2018
Clinical study on thalidomide combined with cinobufagin to treat lung cancer cachexia. Journal of cancer research and therapeutics, 2018, Volume: 14, Issue:1 Topics: Aged; Bufanolides; Cachexia; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Lung	2018
Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling. Medical science monitor : international medical journal of experimental and clinical research, 2018, May-15, Volume: 24 Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Mo	2018
Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast. European journal of cancer (Oxford, England : 1990), 2019, Volume: 110 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Immunological; Carcinoma, Non-	2019
Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC. European journal of pharmacology, 2019, Aug-05, Volume: 856 Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Cycle; Cell Line, T	2019
Mesothelioma: closer to the target? The Lancet. Oncology, 2013, Volume: 14, Issue:6 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lung Neopla	2013
Combination therapy with carboplatin and thalidomide suppresses tumor growth and metastasis in 4T1 murine breast cancer model. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2014, Volume: 68, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Line, Tumor; D	2014
Clinical activity of lenalidomide in visceral human immunodeficiency virus-related Kaposi sarcoma. JAMA dermatology, 2013, Volume: 149, Issue:11 Topics: AIDS-Related Opportunistic Infections; Angiogenesis Inhibitors; Antiretroviral Therapy, Highly Activ	2013
Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy. Cancer biology & therapy, 2014, Mar-01, Volume: 15, Issue:3 Topics: Adenomatous Polyposis Coli; Adult; Angiogenesis Inhibitors; Antibody-Dependent Cell Cytotoxicity; An	2014
Thalidomide therapy for pruritus in the palliative setting--a distinct subset of patients in whom the benefit may outweigh the risk. Journal of pain and symptom management, 2014, Volume: 48, Issue:2 Topics: Aged; Antipruritics; Carcinoma, Non-Small-Cell Lung; Fatal Outcome; Female; Humans; Immunosuppressiv	2014
Metastasized Leydig cell tumor in a dog. Schweizer Archiv fur Tierheilkunde, 2015, Volume: 157, Issue:2 Topics: Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Che	2015
Thalidomide Combined with Chemotherapy in Treating Patients with Advanced lung Cancer. Asian Pacific journal of cancer prevention : APJCP, 2016, Volume: 17, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female;	2016
Pleural effusion as a manifestation of multiple myeloma. BMJ case reports, 2016, Aug-12, Volume: 2016 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Diagnosis, Differen	2016
Anticancer effects of novel thalidomide analogs in A549 cells through inhibition of vascular endothelial growth factor and matrix metalloproteinase-2. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017, Volume: 85 Topics: A549 Cells; Adenocarcinoma; Animals; Apoptosis; Cell Movement; Cell Survival; Female; Gene Expressio	2017
Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma: A case report. Medicine, 2017, Volume: 96, Issue:1 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy,	2017
Metastatic hepatic epithelioid hemangioendothelioma in a teenage girl. Journal of pediatric hematology/oncology, 2008, Volume: 30, Issue:7 Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Ce	2008
The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvascular research, 2009, Volume: 77, Issue:2 Topics: Adherens Junctions; Angiogenesis Inhibitors; Animals; Antigens, CD; Antineoplastic Agents; Basic Hel	2009
Small studies: strengths and limitations. The European respiratory journal, 2008, Volume: 32, Issue:5 Topics: Antineoplastic Agents; Clinical Trials as Topic; Data Interpretation, Statistical; Diet Therapy; Hum	2008
Thalidomide suppressed the growth of 4T1 cells into solid tumors in Balb/c mice in a combination therapy with the oncolytic fusogenic HSV-1 OncdSyn. Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:6 Topics: Animals; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Combined Modality Therapy; Fema	2009
Metronomic paclitaxel and thalidomide for rapidly metastatic primary vulvar malignant rhabdoid tumor. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2009, Volume: 106, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Administration Sched	2009
Thalidomide in small cell lung cancer: wrong drug or wrong disease? Journal of the National Cancer Institute, 2009, Aug-05, Volume: 101, Issue:15 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Ne	2009
Re: Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. Journal of the National Cancer Institute, 2009, Dec-02, Volume: 101, Issue:23 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progre	2009
Targeted therapies: Thalidomide in lung cancer therapy-what have we learned? Nature reviews. Clinical oncology, 2010, Volume: 7, Issue:3 Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Humans; Lung Neoplasms; Neovascularization, Patho	2010
Antitumor and antiangiogenic effects of GA-13315, a gibberellin derivative. Investigational new drugs, 2012, Volume: 30, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line,	2012
The antimalarial agent artesunate possesses anticancer properties that can be enhanced by combination strategies. International journal of cancer, 2011, Mar-15, Volume: 128, Issue:6 Topics: Antimalarials; Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Artesunate; Blotting, W	2011
Unmet challenges in the use of novel agents in locally advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Feb-20, Volume: 30, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung	2012
Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide. British journal of cancer, 2012, Mar-13, Volume: 106, Issue:6 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carbopla	2012
Thalidomide attenuates mammary cancer associated-inflammation, angiogenesis and tumor growth in mice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2012, Volume: 66, Issue:7 Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Female; Fibroblast Growth Factor 1; Gene Exp	2012
Unexpected remission of hepatocellular carcinoma (HCC) with lung metastasis to the combination therapy of thalidomide and cyproheptadine: report of two cases and a preliminary HCC cell line study. BMJ case reports, 2012, Oct-12, Volume: 2012 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Survival; Cyprohepta	2012
Toxic neuropathy in patients with pre-existing neuropathy. Neurology, 2003, Jan-28, Volume: 60, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Dose-Respo	2003
Effects of thalidomide on the expression of angiogenesis growth factors in human A549 lung adenocarcinoma cells. International journal of molecular medicine, 2003, Volume: 11, Issue:6 Topics: Adenocarcinoma; Angiogenesis Inhibitors; Base Sequence; Cell Line, Tumor; DNA, Complementary; Down-R	2003
For investigational targeted drugs, combination trials pose challenges. Journal of the National Cancer Institute, 2003, Dec-03, Volume: 95, Issue:23 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; A	2003
[Report of two cases with pleural effusion and ascites that responded dramatically to the combination of thalidomide, celecoxib, irinotecan, and CDDP infused in thoracic and abdominal cavities]. Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:4 Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Camptothecin;	2004
Effect of thalidomide on growth and metastasis of canine osteosarcoma cells after xenotransplantation in athymic mice. American journal of veterinary research, 2004, Volume: 65, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Dimethyl Sulfoxide; Dog Diseases; Dogs; Dose-Response Relationship	2004
The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines: possible involvement in the PPARgamma pathway. Carcinogenesis, 2004, Volume: 25, Issue:10 Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Non-Small-Cell Lung; Cell Division; Female; Humans; Lun	2004
Very good partial response in a patient with MALT-lymphoma of the lung after treatment with low-dose thalidomide. Leukemia & lymphoma, 2005, Volume: 46, Issue:9 Topics: Humans; Lung Neoplasms; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Thalidomide; Tomography,	2005
[A case report of chemotherapy with thalidomide, celecoxib and gemcitabine in the treatment of patients with brain metastases from lung cancer]. No shinkei geka. Neurological surgery, 2005, Volume: 33, Issue:10 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lu	2005
[Anti-tumor effect of thalidomide and paclitaxel on hepatocellular carcinoma in nude mice]. Chinese medical journal, 2005, Oct-20, Volume: 118, Issue:20 Topics: Animals; Antigens, CD34; Cell Line, Tumor; Humans; Liver Neoplasms, Experimental; Lung Neoplasms; Ma	2005
Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: importance of optimal scheduling to exploit the 'normalization' window of the tumor vasculature. Cancer letters, 2006, Nov-28, Volume: 244, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Chromatography, High Pressure L	2006
[Is small cell lung cancer an orphan disease?]. Revue de pneumologie clinique, 2006, Volume: 62 Spec no 1 Topics: Administration, Oral; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytoge	2006
Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury. International journal of radiation oncology, biology, physics, 2006, Oct-01, Volume: 66, Issue:2 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Non-Small-Cell Lung; Female; Fibroblast	2006
A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Dec-01, Volume: 12, Issue:23 Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Prolife	2006
Thalidomide for treating metastatic hepatocellular carcinoma: a pilot study. The Korean journal of internal medicine, 2006, Volume: 21, Issue:4 Topics: Adult; Bone Neoplasms; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Immunosuppressi	2006
Thalidomide in small-cell lung cancer: is it a tombstone? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jan-01, Volume: 26, Issue:1 Topics: Angiogenesis Inhibitors; Carcinoma, Small Cell; Disease-Free Survival; Humans; Lung Neoplasms; Survi	2008
Thalidomide promotes metastasis of prostate adenocarcinoma cells (PA-III) in L-W rats. Cancer letters, 1996, Mar-19, Volume: 101, Issue:1 Topics: Adenocarcinoma; Animals; Immunosuppressive Agents; Lung Neoplasms; Lymphatic Metastasis; Male; Neopl	1996
Thalidomide for distressing night sweats in advanced malignant disease. Palliative medicine, 1998, Volume: 12, Issue:3 Topics: Fever; Humans; Hyperhidrosis; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Thalidomide	1998
[Many epoch-making discoveries--but also big misjudgements]. Lakartidningen, 1999, Dec-22, Volume: 96, Issue:51-52 Topics: Avitaminosis; Contraceptive Agents; Eugenics; Health Knowledge, Attitudes, Practice; History of Medi	1999
Thalidomide and irinotecan-associated diarrhea. American journal of clinical oncology, 2002, Volume: 25, Issue:3 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea;	2002
Tumour-incidence in progeny of thalidomide-treated mice. British journal of cancer, 1967, Volume: 21, Issue:2 Topics: Abnormalities, Drug-Induced; Animals; Animals, Newborn; Carcinoma, Hepatocellular; Female; Hodgkin D	1967
Sensitivity of newborn mice to carcinogenic agents. Food and cosmetics toxicology, 1968, Volume: 6, Issue:5 Topics: Adenocarcinoma; Adenoma; Animals; Animals, Newborn; Benz(a)Anthracenes; Carcinogens; Carcinoma, Hepa	1968

thalidomide and Cancer of Lung